SEC Form 10-K filed by Niagen Bioscience Inc.
$NAGE
Medicinal Chemicals and Botanical Products
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/27/2025 | $13.00 | Buy | Canaccord Genuity |
Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will present at the East Coast IDEAS Investor Conference on Thursday, June 11, 2026, at The Westin Times Square in New York, NY. IDEAS Conferences provide independent regional venues for quality companies to present their investment merits to influential audiences of investment professionals, offering investor-sponsored events designed to benefit regional investment communities. Niagen Bioscience CEO, Rob Fried, will present on Thursday, June 11, from 2:40 - 3:15 PM ET in the Presenting Room. The pres
The program has supported more than 300 research collaborations across leading institutions worldwide, contributing to over 45 published human clinical studies on Niagen® and advancing understanding of NAD+ biology beyond blood biomarkers into clinically relevant tissues and systems Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the official renaming of the ChromaDex External Research Program (CERP) to the Niagen Research Program, reflecting the Company's name evolution with a focus on advancing the understanding and applications of NAD+ through its flagship ingredient, N
Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior leadership will participate in the following upcoming conferences: 31st Annual Sohn Investment Conference Location: Jazz at Lincoln Center's Frederick P. Rose Hall Date: May 12, 2026 Format: Emerging Company Pavilion, a curated showcase of 8-10 select companies Management: Ozan Pamir, CFO 4th Annual Benchmark Consumer One-On-One Conference Location: New York Athletic Club Date: May 19, 2026 Format: One-on-one meetings Management: Rob Fried, CEO, and Ozan Pamir, CFO If you would like t
4 - Niagen Bioscience, Inc. (0001386570) (Issuer)
4 - Niagen Bioscience, Inc. (0001386570) (Issuer)
4 - Niagen Bioscience, Inc. (0001386570) (Issuer)
8-K - Niagen Bioscience, Inc. (0001386570) (Filer)
10-Q - Niagen Bioscience, Inc. (0001386570) (Filer)
DEFA14A - Niagen Bioscience, Inc. (0001386570) (Filer)
Canaccord Genuity initiated coverage of Niagen Bioscience with a rating of Buy and set a new price target of $13.00
4 - Niagen Bioscience, Inc. (0001386570) (Issuer)
Appointment of renowned gerontologist and mitochondrial biology expert underscores Niagen Bioscience's commitment to advancing cutting-edge NAD+ and healthspan research Niagen Bioscience, Inc. (NASDAQ:NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, is pleased to announce the appointment of Dr. Pinchas Cohen to its Scientific Advisory Board (SAB). Dr. Cohen is an internationally recognized leading expert in healthy aging and mitochondrial biology. He serves as Dean of the University of Southern California (USC) Leonard Davis School of Gerontology and is a Distinguished Professor of Gerontology
Net sales increased to $31.5 million Gross margin improved to 63.5% Net income of $6.3 million, up $1.3 million from the prior year and adjusted EBITDA of $3.8 million Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2026. First Quarter 2026 Financial Highlights Total net sales increased 3% to $31.5 million, including $22.4 million from Tru Niagen®. Excluding the recently sold Analytical Reference Standards and Services segment from both periods, net sales rose 5% to $31.1 million. Gross margin of 63.5%, reflecting continued strength in business mix. Net income of $6.3 million, including a $4.8 million gain on the divestiture
Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference call on Wednesday, May 6, 2026, at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2026. The financial results will be reported in a press release after the close of regular stock market trading hours on Wednesday, May 6, 2026. Investor Conference Call: A live webcast will be held on Wednesday, May 6, 2026, at 4:30 p.m. Eastern Daylight Time (1:30 p.m. Pacific Daylight Time) to discuss Niagen Bioscience's first quarter financial results and provide a
Net sales increased 30% year-over-year to $129.4 million in 2025 Gross margin increased 250 bps year-over-year to 64.3% in 2025 Net income increased 103% year-over-year to $17.4 million in 2025 Adjusted EBITDA increased 139% year-over-year to $20.4 million in 2025 Cash and cash equivalents totaled $64.8 million at December 31, 2025 compared to $44.7 million at December 31, 2024 Full year 2026 net sales outlook reflects between 10-15% growth, excluding the recently sold reference standards segment Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced its fourth quarter and fiscal year 2025 financial results. Fourth Quarter 2025 Financial Highlights Compared to Prior Year Quarter Total